US Launch And EMA Approval Will Expand Global Reach

Amid leadership changes and a recapitalization that add near-term execution risk despite long-term potential for mavorixafor in a substantial unmet market, analysts have lowered their price target for X4 Pharmaceuticals from $19.75 to $8.70. Analyst Commentary Leadership overhaul and new senior management introduce execution uncertainty but may improve strategic direction.

Analysts have lowered their price target for X4 Pharmaceuticals from $23.25 to $19.75, citing increased execution risks and near-term uncertainty from a leadership overhaul, tempered by optimism over recent recapitalization and the long-term potential of mavorixafor. Analyst Commentary Recent complete overhaul of the senior leadership team introduces uncertainty but also the potential for strategic renewal.

A significant reduction in X4 Pharmaceuticals’ future P/E signals lower growth expectations or improved earnings outlook, while a decreased discount rate indicates lower perceived risk, contributing to a sharp downward revision in the fair value estimate from $41.08 to $23.25. What's in the News X4 Pharmaceuticals completed a private placement, issuing 11,040,776 shares at $1.42 and 48,852,772 pre-funded warrants at $1.419, raising $85 million, led by Coastlands Capital LP and supported by top life science investors.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 27.1x to 30.4x.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has increased revenue growth from 53.6% to 270.5%, increased profit margin from 10.5% to 19.3%, decreased future PE multiple from 29.7x to 26.6x, decreased discount rate from 11.6% to 9.2% and increased shares outstanding growth rate from 0.0% to 0.0%.